A J&J unit pays $360 million for illegally using a charity to pay kickbacks to Medicare patients

first_img Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. About the Author Reprints By Ed Silverman Dec. 6, 2018 Reprints Mel Evans/AP What’s included? Pharmalot [email protected] Log In | Learn More A J&J unit pays $360 million for illegally using a charity to pay kickbacks to Medicare patients A Johnson & Johnson (JNJ) unit agreed to pay $360 million to resolve charges of illegally using a supposedly independent charity to pay kickbacks to Medicare patients as a way to cover their out-of-pocket costs.The settlement comes more than two years after federal prosecutors issued a subpoena in connection with an investigation of payments that Actelion Pharmaceuticals, which J&J acquired last year, made to Caring Voice Coalition during 2014 and 2015. The charity provided financial assistance to patients who would not otherwise have been able to afford several medicines for combating high blood pressure in the lungs.center_img What is it? Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Tags drug pricingMedicarepharmaceuticalsSTAT+ Ed Silverman Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.last_img read more